Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report details a specific share repurchase transaction executed on February 16, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 420,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,426.5 pence per share; lowest price paid was 1,404.0 pence per share.
- Treasury Holdings (Settled): 502,862,927 shares (9.05% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,192,927 shares (9.98% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,050,618,069 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 420,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.98% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,050,618,069) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (9.98% including unsettled shares).
- Note that the repurchase price range (1,404.0 to 1,426.5 pence) reflects market conditions on February 16, 2012.